Support to pharmaceutical MSME clusters in Himachal Pradesh under SPI - 4th August 2026 - Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals - Gazette Notification PDF
Issued by Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals
Read or download the official PDF of this gazette notification issued by the Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals on 4th August 2026. Classified under Press Release.
Executive Summary & Key Takeaways
Executive Summary This report details the financial and infrastructural support provided to pharmaceutical MSME clusters in Himachal Pradesh under the "Strengthening of Pharmaceuticals Industry" (SPI) scheme. It highlights the progress of common facility projects and technology upgradation incentives sanctioned across the 2022–2026 period. Key focus areas include the status of funding releases for R&D facilities and pending approvals for pharmaceutical units awaiting scheme extensions.
Key Points / Main Content
Assistance to Pharmaceutical Industry for Common Facilities (APICF)
- Purpose: To strengthen existing pharmaceutical clusters by supporting the creation of common infrastructure for sustained growth.
- M/s Welzo Research & Development Private Limited: This project for an R&D and Testing Laboratory is completed. Total grants released between FY 2022-23 and FY 2025-26 amount to approximately ₹19.53 crore.
- Himachal Pradesh Testing Lab Limited (HPTLL): Approved in FY 2025-26 for ₹17.87 crore to establish a Common Facility Centre for R&D and a centre of excellence for skill development.
- Funding Status for HPTLL: Financial assistance is currently withheld pending the completion of procedural requirements by the entity.
- Pending Proposals: There are no pending proposals for Himachal Pradesh under the APICF sub-scheme.
Revamped Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS)
- Objective: To facilitate technology and process upgrades for pharmaceutical units to meet Revised Schedule-M and WHO-Good Manufacturing Practices (WHO-GMP) standards.
- Approved Units: In Solan District, 16 units were approved for ₹17.19 crore in FY 2024-25, and 27 units were approved for ₹29.02 crore in FY 2025-26.
- Incentive Disbursement: To date, incentives totaling ₹6.42 crore have been released to seven of the approved pharmaceutical units.
- Application Restrictions: 21 applications from Himachal Pradesh remain pending due to temporary restrictions while the Expenditure Finance Committee/Standing Finance Committee decides on the extension of the sub-scheme.
Impact Analysis
Pharmaceutical MSMEs in Solan District Impact: Units gain access to significant financial incentives to modernize their facilities and achieve international certification standards (WHO-GMP). Action Required: Approved units must ensure compliance with scheme guidelines to receive sanctioned incentives; pending applicants must await the finalization of the sub-scheme extension.
M/s Himachal Pradesh Testing Lab Limited (HPTLL) Impact: The entity has been sanctioned ₹17.87 crore for R&D and skill development infrastructure but has not yet received the funds. Action Required: Must fulfill the specific procedural requirements outlined under the APICF sub-scheme to facilitate the release of financial assistance.
Expenditure Finance Committee / Standing Finance Committee Impact: The progress of 21 pending technology upgradation applications is currently dependent on their administrative decisions. Action Required: Finalize the decision regarding the extension of the RPTUAS sub-scheme to clear the backlog of applications.